On November 10, GENSCRIPT B-1K rose 8.88% in regular trading, trading at HK$34.68, with turnover of HK$217 million.
The move was tied to a fresh broker view after the company’s recent investor day, where management discussed AIDD opportunities, platform buildout, business positioning, and long-term growth strategy. The update said the addressable market for life science AIDD could grow at a 50% to 80% compound rate over the next three years, with AIDD expected to drive wet-lab orders through new customer additions, faster iteration cycles, higher validation throughput, and deeper experimental demand.
Recent sector strength also provided support, with peers including WUXI APPTEC, WUXI BIO, XTALPI, and INSILICO moving higher, reinforcing the market’s focus on AI-enabled drug discovery and outsourced life sciences services.
(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)
Comments